NF-κB Signaling as a Central Driver of Cancer Cachexia
Cancers · 09.02.2026 · 18 (4) · 557
DOI: 10.3390/cancers18040557 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 09.02.2026. Verfasst von Yan Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Southeast University Affiliated Nantong First People's Hospital, Nantong 226001, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Nantong First People's Hospital Provincial and Ministerial Level High-level Science and Technology Project Cultivation Fund, The Nantong Municipal Health Commission Scientific Research Project (Directive), Nantong First People’s Hospital Provincial and Ministerial Level High-level Science and Technology Project Cultivation Fund.
Abstract (Originalsprache)
Cancer cachexia is a multifactorial metabolic syndrome characterized by progressive skeletal muscle wasting, chronic systemic inflammation, and profound metabolic imbalance. Sustained activation of the nuclear factor κB (NF-κB) signaling pathway lies at the core of its pathogenesis, driving muscle proteolysis, impairing regenerative capacity, disrupting adipose tissue homeostasis, and promoting insulin resistance and anorexia. By transcriptionally regulating catabolic and pro-inflammatory gene programs across skeletal muscle, adipose tissue, the liver, and the central nervous system, NF-κB establishes a self-amplifying inflammatory–metabolic loop that perpetuates tissue wasting and systemic dysfunction. Accumulating preclinical and clinical evidence identifies NF-κB as a viable therapeutic target in cancer cachexia. Pharmacologic inhibitors (e.g., SR12343, DHMEQ), anti-inflammatory strategies (e.g., nonsteroidal anti-inflammatory drugs and IL-6 receptor–targeting antibodies), and nutritional interventions (e.g., omega-3 fatty acids) have shown efficacy in attenuating cachexia-associated inflammation, metabolic dysregulation, and tissue loss. Notably, emerging multimodal approaches integrating NF-κB modulation with metabolic support, chemotherapy, and behavioral interventions demonstrate synergistic benefits. This review integrates current mechanistic insights and therapeutic advances, highlighting NF-κB as a central pathogenic axis and a compelling target for translational intervention in cancer cachexia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, Southeast University Affiliated Nantong First People's Hospital, Nantong 226001, China.
- School of Medicine, Nantong University, Nantong 226001, China.
- Department of General Surgery, Haimen Traditional Chinese Medicine Hospital, Haimen 226100, China.
- Department of Thoracic Surgery, Southeast University Affiliated Nantong First People's Hospital, Nantong 226001, China.
- Department of Pathology, Medical School of Nantong University, Nantong 226001, China.
ORCID-Profile: Yan Li, Shengguang Ding
Förderung
- The Nantong First People's Hospital Provincial and Ministerial Level High-level Science and Technology Project Cultivation Fund
- The Nantong Municipal Health Commission Scientific Research Project (Directive)
- Nantong First People’s Hospital Provincial and Ministerial Level High-level Science and Technology Project Cultivation Fund
- Nantong Municipal Health Commission Scientific Research Project
- Nantong Municipal Health Commission
Zitieren
APA
Li, Y., Jiang, H., Chen, R., Huang, H., & Ding, S. (2026). NF-κB Signaling as a Central Driver of Cancer Cachexia. Cancers, 18(4), 557. https://doi.org/10.3390/cancers18040557
Vancouver
Li Y, Jiang H, Chen R, Huang H, Ding S. NF-κB Signaling as a Central Driver of Cancer Cachexia. Cancers. 2026;18(4):557. doi:10.3390/cancers18040557
BibTeX
@article{Li2026,
author = {Li, Yan and Jiang, Hao and Chen, Rui and Huang, Haitao and Ding, Shengguang},
title = {NF-κB Signaling as a Central Driver of Cancer Cachexia},
journal = {Cancers},
year = {2026},
volume = {18},
number = {4},
pages = {557},
doi = {10.3390/cancers18040557}
}
EUVIMED